Galectin Therapeutics reported 4.02 in Sales Revenues for its fiscal quarter ending in March of 2023.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Merck USD 16.29B 110M Mar/2026